K-Cab Dosage & Drug Information

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Storage MIMS Class ATC Classification Regulatory Classification Presentation/Packing

Concise Prescribing Info

Contents

Tegoprazan

Indications/Uses

Erosive/non-erosive GERD, gastric ulcer. Eradication of H. pylori w/ appropriate antibiotic therapy in patients w/ peptic ulcer &/or chronic atrophic gastritis.

Click to view K-Cab detailed prescribing information

Dosage/Direction for Use

Adult Erosive GERD 50 mg once daily for 4 wk. Additional 4-wk may be considered in patients who do not heal or have persistent symptoms after 4 wk. Non-erosive GERD 50 mg once daily for 4 wk. Gastric ulcer 50 mg once daily for 8 wk. Eradication of H. pylori in patients w/ peptic ulcer &/or chronic atrophic gastritis Tegoprazan 50 mg, clarithromycin 500 mg & amoxicillin 1 g bid for 7 days.

Click to view K-Cab detailed prescribing information

Overdosage

View K-Cab overdosage for action to be taken in the event of an overdose.

Administration

May be taken with or without food.

Contraindications

Hypersensitivity to tegoprazan or substituted benzimidazoles. Patients taking atazanavir, nelfinavir or rilpivirin-containing products. Pregnancy & lactation.

Click to view K-Cab detailed prescribing information

Special Precautions

Hepatic & renal impairment. Elderly. Childn.

Click to view K-Cab detailed prescribing information

Use In Pregnancy & Lactation

Click to view K-Cab detailed prescribing information

Adverse Reactions

Nausea, diarrhea, dyspepsia, nasopharyngitis, viral upper resp tract infection, chest discomfort.

Click to view K-Cab detailed prescribing information

Drug Interactions

Decreased absorption of ketoconazole, itraconazole, ampicillin ester, atazanavir, Fe salts, erlotinib, gefitinib & mycophenolate mofetil. Increase absorption w/ digoxin. Increased absorption of digoxin. Decreased plasma conc of atazanavir, nelfinavir or rilpivirin. Increased AUC w/ clarithromycin. Increased AUC w/ clarithromycin.

Click to view K-Cab detailed prescribing information

Storage

View K-Cab storage conditions for details to ensure optimal shelf-life.

Description

View K-Cab description for details of the chemical structure and excipients (inactive components).

Action

View K-Cab mechanism of action for pharmacodynamics and pharmacokinetics details.

MIMS Class

Antacids, Antireflux Agents & Antiulcerants

ATC Classification

A02BC09 - tegoprazan ; Belongs to the class of potassium-competitive acid blocker. Used in the treatment of peptic ulcer and gastro-oesophageal reflux disease (GERD).

Regulatory Classification

Presentation/Packing

Form

K-Cab FC tab 50 mg

Packing/Price

30's (P3,450/box, P115/film-coated tab)

K-Cab

Manufacturer:

HK Inno.N

Distributor:

Metro Pharma